FDA inspection uncovers cherry-colored antibiotic residue on equipment at Teva’s New Jersey site

An FDA inspection report on Teva’s manufacturing site in New Jersey has revealed issues with both equipment cleaning and quality.

The three-page report, which was obtained by Endpoints News via a FOIA request from the FDA, showed several observations from its inspection, which took place between Nov. 1 and...

Click to view original post